0.8581
price down icon3.37%   -0.0299
after-market Handel nachbörslich: .90 0.0419 +4.88%
loading
Schlusskurs vom Vortag:
$0.888
Offen:
$0.903
24-Stunden-Volumen:
526.52K
Relative Volume:
0.67
Marktkapitalisierung:
$113.52M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-0.2813
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+6.08%
1M Leistung:
+4.49%
6M Leistung:
-20.55%
1J Leistung:
-81.47%
1-Tages-Spanne:
Value
$0.8101
$0.95
1-Wochen-Bereich:
Value
$0.7747
$1.015
52-Wochen-Spanne:
Value
$0.7082
$4.74

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Name
Firmenname
Rapt Therapeutics Inc
Name
Telefon
(650) 489-9000
Name
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
67
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
RAPT's Discussions on Twitter

Vergleichen Sie RAPT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RAPT
Rapt Therapeutics Inc
0.8581 107.01M 3.25M -116.80M -98.17M -3.05
Biotechnology icon
ONC
Beigene Ltd Adr
238.76 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.03 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2548 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.85 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.69 5.92B 0 -153.72M -103.81M -2.00

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-26 Hochstufung H.C. Wainwright Neutral → Buy
2024-11-13 Herabstufung Stifel Buy → Hold
2024-11-11 Herabstufung JP Morgan Neutral → Underweight
2024-11-11 Herabstufung Piper Sandler Overweight → Neutral
2024-05-14 Herabstufung Wolfe Research Outperform → Peer Perform
2024-05-10 Herabstufung Barclays Overweight → Equal Weight
2024-05-10 Herabstufung Guggenheim Buy → Neutral
2024-02-22 Herabstufung UBS Buy → Neutral
2024-02-21 Herabstufung H.C. Wainwright Buy → Neutral
2024-02-21 Herabstufung JP Morgan Overweight → Neutral
2024-02-21 Herabstufung Leerink Partners Outperform → Market Perform
2024-02-20 Herabstufung Cantor Fitzgerald Overweight → Neutral
2024-02-16 Eingeleitet Evercore ISI Outperform
2024-02-15 Eingeleitet Wolfe Research Outperform
2023-09-14 Eingeleitet Berenberg Buy
2023-08-09 Eingeleitet Stifel Buy
2023-06-15 Eingeleitet Barclays Overweight
2023-01-04 Eingeleitet Guggenheim Buy
2022-12-01 Eingeleitet Goldman Buy
2022-09-21 Eingeleitet CapitalOne Overweight
2022-05-24 Fortgesetzt Cantor Fitzgerald Overweight
2021-12-09 Eingeleitet JP Morgan Overweight
2021-08-12 Eingeleitet SVB Leerink Outperform
2021-06-21 Eingeleitet Piper Sandler Overweight
2020-06-01 Eingeleitet H.C. Wainwright Buy
2020-05-19 Eingeleitet Cantor Fitzgerald Overweight
2020-04-13 Eingeleitet ROTH Capital Buy
2019-11-25 Eingeleitet BMO Capital Markets Outperform
2019-11-25 Eingeleitet UBS Buy
2019-11-25 Eingeleitet Wells Fargo Outperform
Alle ansehen

Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten

pulisher
06:51 AM

UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Sto - GuruFocus

06:51 AM
pulisher
May 19, 2025

Comerica Bank Purchases Shares of 58,040 RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 19, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Sells 105,231 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 18, 2025
pulisher
May 16, 2025

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

May 16, 2025
pulisher
May 09, 2025

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World

May 09, 2025
pulisher
May 09, 2025

RAPT Therapeutics Reports Improved Q1 2025 Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

RAPT Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 05, 2025

RAPT Therapeutics Reports Third Quarter 2024 Financial Results - ADVFN

May 05, 2025
pulisher
May 05, 2025

RAPT Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 04, 2025

Renaissance Technologies LLC Has $584,000 Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 04, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Raises Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 03, 2025
pulisher
May 02, 2025

There is no way RAPT Therapeutics Inc (RAPT) can keep these numbers up - Sete News

May 02, 2025
pulisher
May 01, 2025

A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Market Recap: RAPT Therapeutics Inc (RAPT)’s Positive Momentum, Closing at 0.93 - DWinneX

May 01, 2025
pulisher
May 01, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Acquired by Geode Capital Management LLC - Defense World

May 01, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 24, 2025

RAPT Therapeutics Inc (RAPT) is a good investment, but the stock may be overvalued - uspostnews.com

Apr 24, 2025
pulisher
Apr 21, 2025

Stock Surge: RAPT Therapeutics Inc (RAPT) Closes at 0.79, Marking a -1.32 Increase/Decrease - DWinneX

Apr 21, 2025
pulisher
Apr 18, 2025

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth? - Yahoo Finance

Apr 18, 2025
pulisher
Apr 18, 2025

RAPT stock touches 52-week low at $0.78 amid sharp annual decline - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

RAPT stock touches 52-week low at $0.78 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 15, 2025

Rapt Therapeutics appoints Jessica Savage as VP, clinical development - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World

Apr 13, 2025
pulisher
Mar 20, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN

Mar 19, 2025
pulisher
Mar 13, 2025

Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks

Mar 10, 2025
pulisher
Mar 07, 2025

RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 07, 2025
pulisher
Mar 07, 2025

Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan

Mar 07, 2025
pulisher
Mar 07, 2025

Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c) - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Can RAPT's $231M War Chest and New Food Allergy Drug Transform Its Future? - StockTitan

Mar 06, 2025
pulisher
Mar 03, 2025

RAPT Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Mar 03, 2025
pulisher
Feb 27, 2025

RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 23, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World

Feb 23, 2025
pulisher
Feb 16, 2025

Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha

Feb 16, 2025
pulisher
Feb 14, 2025

SG Americas Securities LLC Purchases 42,636 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

Feb 14, 2025

Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$581.44
price down icon 0.60%
$1.39
price up icon 6.92%
$32.50
price down icon 0.28%
$289.00
price down icon 1.22%
$4.2299
price up icon 5.48%
$72.69
price down icon 1.89%
Kapitalisierung:     |  Volumen (24h):